MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • MassDevice Today
    • Cardiovascular
    • Clinical Trials
    • Legal News
    • Orthopedics
    • Regulatory/Compliance
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • More MedTech
    • Cosmetic/Aesthetic
    • Diabetes
    • Dialysis
    • Distribution
    • Imaging
    • Otolaryngology Ear, Nose & Throat
    • Pharma
    • Respiratory
    • Wound Care
  • Blog
  • DeviceTalks Podcasts
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • White Papers
  • DeviceTalks
Home » Boston Scientific closes $400m NxThera buy

Boston Scientific closes $400m NxThera buy

April 30, 2018 By Brad Perriello Leave a Comment

Share

Boston Scientific acquires NxTheraBoston Scientific (NYSE:BSX) said today that it closed the $406 million acquisition of NxThera and its Rezūm benign prostatic hyperplasia device, which uses steam to ablate excess prostate tissue.

The deal called for $306 million in up-front cash from Marlborough, Mass.-based Boston Scientific, with another $100 million in potential milestones over the next four years. Boston, which in December 2015 led a $40 million funding round for NxThera, said the existing investment means it will have to put $240 million down and another $85 million on the table in milestones. NxThera is based in Maple Grove, Minn. When Boston Scientific paid $1.6 billion to Endo (NSDQ:ENDP) for the urology portfolio Endo had acquired from American Medical Systems, it also inherited an earlier investment in NxThera by AMS.

“We are confident in the potential for this system to help patients with BPH and increase the number of men choosing MITs, because it offers long-term relief from symptoms without the side effects of medications,” medsurg president Dave Pierce said in prepared remarks. “The minimally invasive therapy segment is the fastest growing category in the treatment of BPH and, as an office-based procedure, the Rezūm system is appealing to patients, clinicians and payers.”

The deal involves plans to spin-out a new company to commercialize technology for treating cancer, NxThera CEO Bob Paulson told MassDevice.com when the deal was announced in March.

“As part of this transaction, we are taking the urology cancer applications – prostate cancer, bladder cancer and kidney cancer – that can also utilize our technology. Those are being spun off into a separate, new company that will be owned by the existing investors, including Boston,” Paulson told us. “This will be funded separately and will move forward as a stand-alone entity. This is another chance for our investors down the road to demonstrate the applicability and efficacy of the technology to treat new applications and to be able to determine at that time what the right commercial strategy is and what value that may be to strategic investors.”

In January, NxThera touted three-year results from a 197-patient trial that showed clinically significant and durable improvement in symptomatic relief, with no latent adverse events, no de novo erectile disfunction and a 4.4% re-treatment rate. Rezūm won CE mark approval in the European Union in 2013 and landed 510(k) clearance from the FDA two years later.

Paulson said that the company is hopeful it will continue with further studies of its Rezum technology platform, seeking to further validate the system and explore other possible indications.

“We will continue to gather that data moving forward. There are several additional studies that were in the works, in the pipeline in terms of expanding indications and further demonstrating both the efficacy and durability of the data. The presumption is that those will move forward under Boston’s tutelage,” he told us.

Boston said it expects the buyout, forecast to close during the second quarter, to be immaterial to adjusted earnings per share until the end of 2020.

“The deal is a great combination for patients and urologists because with Boston’s resources and the fact that the global leader in urology, this gives them access to a first line treatment option for BPH which is the largest untapped market in urology and will allow them to offer their patients an entire continuum of care treatment options from a first line treatment all the way down to a surgical treatment,” Paulson told us. “So, this is a really huge win for physicians and patient choice for treating BPH.”

Filed Under: Mergers & Acquisitions, Urology, Wall Street Beat Tagged With: Boston Scientific, NxThera Inc.

In case you missed it

  • Propeller Health study suggests 84% of asthma inhaler use performed incorrectly
  • LivaNova wins Japanese reimbursement for Perceval aortic valve
  • Acelity’s KCI launches Abthera NPWT system in Japan
  • ARS Pharmaceuticals wins fast track status for epinephrine nasal spray
  • Mauna Kea, Cook Medical terminate Cellvizio dev, distro deal
  • Axonics Modulation touts results of sacral neuromodulation study
  • CorMatrix launches FDA IDE Cor Tricuspid ECM cardiac valve trial
  • Philips wins FDA nod for DigitalDiagnost C90 digital radiography system
  • Teleflex shares dip on Q4, 2018 earnings release, restructuring announcement
  • Report: Medtronic to close Portsmouth, N.H. transformative solutions facility
  • Late mortality rates ‘inadvertently reversed’ in 5-year study of paclitaxel-eluting stent
  • NuVasive shares rise on Q4, 2018 EPS beat
  • LivaNova touts CMS trial clearance for vagus nerve depression treatment system
  • Phillips-Medisize is offering connected health data services: Here’s how
  • Abbott, Novo Nordisk ink deal for digital diabetes tools
  • Ocular Therapeutix doses first wet-AMD patient in implant trial
  • Neovasc inks $3m settlement deal with MID, raises $1m

RSS From Medical Design & Outsourcing

  • How to design home healthcare devices that people will use
    Meeting consumer demands for home healthcare technology requires a keen knowledge of user behavior. Here are four ways companies are approaching the market. by Scott Thielman, Product Creation Studio The global smart home healthcare market is exploding as more medical devices are designed for use wherever the patient is, including at home. A report by Research… […]
  • Axonics Modulation touts results of sacral neuromodulation study
    Axonics Modulation Technologies (NSDQ:AXNX) announced positive top-line results from a pivotal study of its novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction. The clinical study demonstrated that patients implanted with the Axonics r-SNM system experienced clinically meaningful and statistically significant improvements in urinary urgency incontinence (UUI) symptoms and quality of… […]
  • Okay Industries appoints new marketing manager
    Okay Industries (New Britain, Conn.) announced that it has appointed Angela Dillon as its new marketing manager. As marketing manager, Dillon willed strategic initiative that will promote the Okay brand, support business development and manage both internal and external communications for talent recruitment and retention. “I am excited to announce this new role for Angela,”… […]
  • SIG Medical wins FDA clearance for rib fracture device
    SIG Medical (Hershey, Penn.) has received FDA 510(k) clearance for its enhanced AdvantageRib System, the K183317. The system is the third rib fracture system from SIG Medical that has received 510(k) clearance recently and is being commercialized. The most recent 510(k) includes new implants that treat patients, as well as the entire spectrum of bone… […]
  • Starr Surgical signs strategic cooperation agreement with Smile Eyes
    Starr Surgical (Monrovia, Calif.) recently announced that it has signed a strategic cooperation agreement with the Smile Eyes group in Germany and Austria. The Smile Eyes group is an alliance of more than 80 eye experts in 13 vision correction eye centers in Germany and Austria. Through the agreement, EVO Visian ICL lenses will be… […]
  • Phillips-Medisize is offering connected health data services: Here’s how
    One of the world’s largest medical device contract manufacturers, Phillips-Medisize is making a business play to provide the technological back end for connected drug delivery devices. Phillips-Medisize used to be all about the housings, assembly and packaging that went into finished drug-delivery devices. Electronics was something that other contract manufacturers did. Within a few years,… […]
  • Summit Medical expands manufacturing facility
    Summit Medical recently announced that it has expanded its St. Paul, Minn. manufacturing facility with an additional 15,000 sq. ft. The addition opened on Feb. 11. The expansion will become a secondary facility for the company’s headquarters that is located less than a mile away. It will also serve as a master distribution center. “The… […]
  • AdvaMed president & CEO Scott Whitaker to participate in keynote interview at DeviceTalks Boston 2019
    WTWH Media and MassDevice.com announced today that Scott Whitaker, president and CEO of AdvaMed, will be a featured keynote speaker at DeviceTalks Boston 2019. DeviceTalks Boston, which takes place on June 5-6, 2019 at the Seaport World Trade Center, brings together engineering, product development and commercialization professionals to share the challenges and best practices of getting medical devices… […]
  • Apollo Endosurgery touts results of stomach-stapling study
      Apollo Endosurgery (NSDQ:APEN) has reported key data from 1,000 patients who underwent endoscopic gastroplasty using the company’s OverStitch device. Published in the journal Gastrointestinal Endoscopy, the data include a mean total weight loss of 14.8%±8.5% at 18 months. Three months following surgery, the impact on obesity-related comorbidities included the complete remission of: 13 of 17 cases… […]
  • Royal Philips introduces new C-arm imaging tech
    Royal Philips (NYSE:PHG) said it has launched a new mobile C-arm imaging platform, Zenition. Mobile C-arms are X-ray systems that are brought into the operating room (OR) to provide live image guidance during a wide range of surgeries including orthopedic, trauma and vascular procedures. The Zenition mobile C-arm platform brings together innovations in image capture, image… […]
  • When human factor specialists become the patient
    By Allison Strochlic, Emergo Group I just had a baby – my second daughter. This means that, like over 98% of my fellow American moms-to-be, I checked into a local hospital to have nurses and doctors oversee what I hoped would be the smooth delivery of my baby. This entitled me to the firsthand experience… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Privacy
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS